Sulphonylureas and hypoglycaemia

British Medical Journal (Clinical research ed.)

Volumn 296, Issue 6627, 1988, Pages 949-950

  Ferner, R E ^a   Neil, Haw ^b  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; HYPOGLYCEMIA; PRIORITY JOURNAL; SHORT SURVEY;

HUMAN; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; SULFONYLUREA COMPOUNDS;

EID: 0023935536     PISSN: 02670623     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.296.6627.949     Document Type: Article

References (31)

1. Clarke B. F. Campbell I. W. Longterm comparative trial of glibenclamide and chlorpropamide in dietfailed maturityonset diabetes. Lancet 1974;i:246-8.
2. Dahlen M. Bergman U. Idman L. Martinsson L. Karlsson G. Epidemiology of hypoglycaemia in patients on oral antidiabetic drugs in the island of Gotland, Sweden. Acta Endocrinol (suppl) 1984;263:abst 21.
3. Potter J. Clarke P. Gale A. E. M. Dave S. H. Tattersall R. B. Insulininduced hypoglycaemia in an accident and emergency department: the tip of an iceberg? Br. Med. f 1982;285:1180-2.
4. Barnett A. H. Leslie D. Watkins P. J. Can insulintreated diabetics be given betaadrenergic blocking drugs? Br. Med. f 1980;280:976-8.
5. Muhlhauser I. Berger M. Sonnenberg G. Koch J. Jorgens V. Schernthaner G. Scholz V. Incidence and management of severe hypoglycaemia in 434 adults with insulindependent diabetes mellitus. Diabetes Care 1985;8:268-73.
6. Casparie A. F. Elving L. D. Severe hypoglycaemia in diabetic patients: frequency, causes, prevention. Diabetes Care 1985;8:141-5.
7. Tunbridge WMG. Factors contributing to deaths of diabetics under fifty years of age. Lancet 1981;ii:569-72.
8. Neil H. A. W. Gatling G. Mather H. M. et al. The Oxford Community Diabetes Study: evidence for an increase in the prevalence of known diabetes. Diabetic Medicine 1987;4:539-43.
9. Campbell I. W. Metformin and glibenclamide: comparative risks. Br. Med. f 1984;289:289.
10. Berger W. Caduff F. Pasquel M. Rump A. Die relative Haufigkeit der schweren Sulfonylharnstoff Hypoglykamie in den letzten 25 Jahren in der Schweiz. Schweiz Med Wochenschr 1986;116: 145-51.
11. Klimt C. R. Knatterud G. L. Meinert C. L. Prout T. E. The University Group Diabetes Program: a study of the effects of hypoglycemic agents on vascular complications in patients with adultonset diabetes. II. Mortality results. Diabetes 1970;19(suppl 2):747-830.
12. Fuller J. H. Clinical trials in diabetes mellitus. In: Mann J. Pylorala K. Teuscher A. eds. Diabetes in epidemiological perspective, Edinburgh: Churchill Livingstone, 1983:265-85.
13. UK Prospective Study of Therapies of MaturityOnset Diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year. Diabetologia 1983;24:404-11.
14. Asplund K. Wiholm B-E, Lithner F. Glibenclamideassociated hypoglycaemia: a report on 57 cases. Diabetologia 1983;24:412-7.
15. Selzer H. S. Druginduced hypoglycaemia: a review based on 473 cases. Diabetes 1972;21:955-66.
16. Sonnenblick M. Shilo S. Glibenclamide induced prolonged hypoglycaemia. Age Ageing 1986;15: 185-9.
17. Johnson S. F. Schade D. S. Peake G. T. Chlorpropamideinduced hypoglycaemia: successful treatment with diazoxide. Am f Med 1977;63:799-804.
18. Ludman P. Mason P. Joplin G. S. Dangerous misuse of sulphonylureas. Br. Med. f 1986;293: 1287-8.
19. Ferner R. E. Chaplin S. Relationship between pharmacokinetics and pharmacodynamics of oral hypoglycaemic agents. Clin Pharmokinet 1987;12:379-401.
20. Frey H. M. M. Rosenlund B. Studies in patients with chlorpropamideinduced hypoglycemia. Diabetes 1970;19:930-7.
21. Rogers H. J. Spector R. G. Morrison P. J. Bradbrook I. D. Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay. Diabetologia 1982;23:37-40.
22. Matsuda A. Kuzuya T. Sugita Y. Kawashima K. Plasma levels of glibenclamide in diabetic patients during routine clinical administration determined by a specific radioimmunoassay. Horm Metab Res 1983;15:425-8.
23. Axelgaard G. Skensved H. Asfeldt V. H. Hypglykaemi ved behandling med sulfonylurinstoffer. Ugeskr Laeger 1986;8:2155-8.
24. Hellman B. Sehlin J. Taljedal I-B. Glibenclamide is exceptional among hypoglycaemic agents in accumulating progressively in Bcell rich pancreatic islets. Acta Endocrinol 1984;105: 385-90.
25. Matthews E. K. Shotton P. A. The control of 86 Rb efflux from rat isolated pancreatic islets by the sulphonylureas tolbutamide and glibenclamide. Br J. Pharmacol 1984;82:689-700.
26. Gale EAM. Hypoglycaemia. Clin Endocrinol Metab 1980;9:461-75.
27. Marks V. Rose F. C. Hypoglycaemia. 2nd ed. Oxford: Blackwell Scientific, 1981:368.
28. Davies D. M. MacIntyre A. Millar E. J. Bell S. M. Mehra S. K. Need for glucagon in severe hypoglycaemia induced by sulphonylurea drugs. Lancet 1967;i:363-4.
29. Pfeifer M. A. Wolter C. F. Samols E. Management of chlorpropamide induced hypoglycaemia with diazoxide. South Med J. 1978;71:606-8.
30. Verschoor L. Uitterlinden P. Lamberts S. W. J. Del Pozo E. The use of a new somatostatin analogue in the treatment of hypoglycaemia in patients with insulinoma. Clin Endocrinol 1986;25:555-60.
31. Neuvonen P. J. Karkkainen S. The effects of charcoal, sodium bicarbonate, and ammonium chloride on chlorpropamide kinetics. Clin Pharmacol Ther 1983;33:386-93.